Supports theoretical mediation of therapeutic effects due to altering the mPFC excitation-to-inhibition signaling ratio.

Psilocybin may preferentially increase GABAergic activity leading to downstream decrease in Glutamatergic cell activity.

Complete ongoing analyses to determine which cell types drive psilocybin-induced changes in mPFC activity.

Test other psychedelic compounds to assess whether they produce similar cellular and network effects to psilocybin.

Examine the ability of psilocybin to facilitate longitudinal alleviation of depressive symptoms.